BRAF mutations have been found to be a driver mutation and maybe a therapy target in patients with non-small-cell lung cancer (NSCLC). We sought to compile the available researches of BRAF mutations to better understand the characteristic of BRAF mutant patients with NSCLC.Methods
We searched published researches involving BRAF mutations and NSCLC. Fifteen reports were identified (published between June 2002 and September 2011). We used direct data as extracted from the author's publication for BRAF mutation frequency and other clinicopathologic analysis.Results
Over 4100 NSCLCs comprising 3383 adenocarcinomas (ADCs) and 842 lung squamous cell carcinomas (SCCs) were pooled from these studies. The frequency of BRAF mutations is ∼2.7% (93 of 3383) in ADCs, and 0.7% in others (P < 0.001). BRAF mutations (including both V600E mutations and non-V600E) were high frequently associated with smoking history (38 of 57 patients and 32 of the 35 patients; 66.7% and 91.4%, respectively, P = 0.007). In lung ADCs subgroup, V600E mutations were frequent in female (40 of 56 patients; 71.4%) while non-V600E mutations were prevalent in males (22 of 35 patients; 62.9%), as indicated by Pearson chi-square analysis (P = 0.001). However, the majority of patients harboring BRAF mutations in SCCs are non-V600E, male, and former or current smokers; leaving only one SCC (16.7%) with V600E mutant.Conclusions
We conducted the largest survey of BRAF mutations in patients with NSCLC to date. BRAF mutations were associated with the gender and smoking history of patients with NSCLC. This characteristics of BRAF mutations may facilitate in selecting patients for therapy targeted BRAF in the future.